Skip to main content

Exhibitor Seminar: AstraZeneca Precision Medicine - HER2-low (IHC 1+ or IHC 2+/ISH-) Is a New Classification of HER2 Expression in Breast Cancer

Date and Time: Wednesday, March 15, 2023, 12:00 PM - 1:00 PM CDT

Faculty: Julie Bridges Steele, MD

Course Description
Improve clinical outcomes by testing for all actionable biomarkers

HER2 has been, and continues to be, a practice-changing biomarker for guiding treatment decisions in breast cancer. Recently, a treatment option became available for certain patients with metastatic breast cancer (mBC), unlocking the need to take a fresh look at HER2 diagnostic approach. In this session, Dr. Bridges Steele will provide you with details about this indication, requirements for diagnostic testing, and a perspective on what this means for pathologists and the pathology laboratory.

Privacy Notice
The webinar is possible through AstraZeneca Precision Medicine. This content is not available for continuing medical education. If you continue to register, you are acknowledging that your information will be shared with the company, including your name, degrees, institution, NPI number, mailing address, email address, and phone number. USCAP has no control over the use of this information.

The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through AstraZeneca Precision Medicine. This activity is not available for CME.